BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36087876)

  • 1. Proton Therapy for 166 Patients with Iris Melanoma: Side Effects and Oncologic Outcomes.
    Gollrad J; Böker A; Vitzthum S; Besserer A; Heufelder J; Gauger U; Böhmer D; Budach V; Zeitz O; Joussen AM
    Ophthalmol Retina; 2023 Mar; 7(3):266-274. PubMed ID: 36087876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Side Effects of Proton Beam Radiotherapy Treatment on Iris Melanoma.
    Eibenberger K; Heimann H; Gatchalian L; Kacperek A; Hussain R
    Ophthalmology; 2023 Sep; 130(9):958-965. PubMed ID: 37169262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes.
    Shields CL; Shah SU; Bianciotto CG; Emrich J; Komarnicky L; Shields JA
    Ophthalmology; 2013 Jan; 120(1):55-61. PubMed ID: 22980742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.
    Riechardt AI; Karle B; Cordini D; Heufelder J; Budach V; Joussen AM; Gollrad J
    Strahlenther Onkol; 2017 Nov; 193(11):943-950. PubMed ID: 28631017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton beam radiotherapy of diffuse iris melanoma in 54 patients.
    Willerding GD; Cordini D; Hackl C; Karle B; Lakotka N; Foerster MH; Bechrakis NN; Heufelder J; Moser L; Joussen AM
    Br J Ophthalmol; 2015 Jun; 99(6):812-6. PubMed ID: 25505288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field).
    Oxenreiter MM; Lane AM; Aronow MB; Shih H; Trofimov AV; Kim IK; Gragoudas ES
    Br J Ophthalmol; 2022 Apr; 106(4):518-521. PubMed ID: 33355171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects.
    Riechardt AI; Klein JP; Cordini D; Heufelder J; Rehak M; Seibel I; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1325-1332. PubMed ID: 29464331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence of iris melanoma after proton beam therapy.
    Sandinha MT; Kacperek A; Errington RD; Coupland SE; Damato B
    Br J Ophthalmol; 2014 Apr; 98(4):484-7. PubMed ID: 24414401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors.
    Riechardt AI; Pilger D; Cordini D; Seibel I; Gundlach E; Hager A; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2263-2269. PubMed ID: 28721444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton beam radiotherapy of iris melanoma.
    Damato B; Kacperek A; Chopra M; Sheen MA; Campbell IR; Errington RD
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):109-15. PubMed ID: 16111578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton Beam Therapy for Iris Melanomas in 107 Patients.
    Thariat J; Rahmi A; Salleron J; Mosci C; Butet B; Maschi C; Lanza F; Lanteri S; Baillif S; Herault J; Mathis T; Caujolle JP
    Ophthalmology; 2018 Apr; 125(4):606-614. PubMed ID: 29128229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases.
    Rahmi A; Mammar H; Thariat J; Angellier G; Herault J; Chauvel P; Kodjikian L; Denis P; Grange JD
    Graefes Arch Clin Exp Ophthalmol; 2014 Sep; 252(9):1515-21. PubMed ID: 25038910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conservative management of suspicious melanocytic lesions of the iris.
    Oxenreiter MM; Lane AM; Jain P; Kim IK; Gragoudas ES
    Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1319-1324. PubMed ID: 30919077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole anterior segment proton beam radiotherapy for diffuse iris melanoma.
    Konstantinidis L; Roberts D; Errington RD; Kacperek A; Damato B
    Br J Ophthalmol; 2013 Apr; 97(4):471-4. PubMed ID: 23298884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse iris melanoma: a report of 25 cases.
    Demirci H; Shields CL; Shields JA; Eagle RC; Honavar SG
    Ophthalmology; 2002 Aug; 109(8):1553-60. PubMed ID: 12153810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.
    Shields CL; Di Nicola M; Bekerman VP; Kaliki S; Alarcon C; Fulco E; Shields JA
    Ophthalmology; 2018 Jun; 125(6):913-923. PubMed ID: 29342436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary Glaucoma due to Iridescent Crystalline Particles Masquerading as Refractory Hypertensive Uveitis in an Eye With Irradiated Iris Melanoma.
    Chahal R; Mohite AA; Heimann H; Bansal A
    J Glaucoma; 2018 Apr; 27(4):385-388. PubMed ID: 29394206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement.
    Gündüz K; Shields CL; Shields JA; Cater J; Freire JE; Brady LW
    Arch Ophthalmol; 1999 Feb; 117(2):170-7. PubMed ID: 10037560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Ab Interno Tumor Treatment After Proton Beam Irradiation.
    Seibel I; Riechardt AI; Heufelder J; Cordini D; Joussen AM
    Am J Ophthalmol; 2017 Jun; 178():94-100. PubMed ID: 28365241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications.
    Shields CL; Naseripour M; Shields JA; Freire J; Cater J
    Am J Ophthalmol; 2003 May; 135(5):648-56. PubMed ID: 12719072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.